
TECH Valuation
Bio-Techne Corp
- Overview
- Forecast
- Valuation
- Earnings
TECH Relative Valuation
TECH's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, TECH is overvalued; if below, it's undervalued.
Historical Valuation
Bio-Techne Corp (TECH) is now in the Undervalued zone, suggesting that its current forward PE ratio of 26.66 is considered Undervalued compared with the five-year average of 43.05. The fair price of Bio-Techne Corp (TECH) is between 68.13 to 101.49 according to relative valuation methord. Compared to the current price of 53.86 USD , Bio-Techne Corp is Undervalued By 20.95%.
Relative Value
Fair Zone
68.13-101.49
Current Price:53.86
20.95%
Undervalued
26.66
PE
1Y
3Y
5Y
Trailing
Forward
19.69
EV/EBITDA
Bio-Techne Corp. (TECH) has a current EV/EBITDA of 19.69. The 5-year average EV/EBITDA is 30.24. The thresholds are as follows: Strongly Undervalued below 16.67, Undervalued between 16.67 and 23.45, Fairly Valued between 37.02 and 23.45, Overvalued between 37.02 and 43.80, and Strongly Overvalued above 43.80. The current Forward EV/EBITDA of 19.69 falls within the Undervalued range.
21.55
EV/EBIT
Bio-Techne Corp. (TECH) has a current EV/EBIT of 21.55. The 5-year average EV/EBIT is 32.57. The thresholds are as follows: Strongly Undervalued below 18.35, Undervalued between 18.35 and 25.46, Fairly Valued between 39.68 and 25.46, Overvalued between 39.68 and 46.79, and Strongly Overvalued above 46.79. The current Forward EV/EBIT of 21.55 falls within the Undervalued range.
6.76
PS
Bio-Techne Corp. (TECH) has a current PS of 6.76. The 5-year average PS is 11.40. The thresholds are as follows: Strongly Undervalued below 5.19, Undervalued between 5.19 and 8.29, Fairly Valued between 14.50 and 8.29, Overvalued between 14.50 and 17.61, and Strongly Overvalued above 17.61. The current Forward PS of 6.76 falls within the Undervalued range.
24.79
P/OCF
Bio-Techne Corp. (TECH) has a current P/OCF of 24.79. The 5-year average P/OCF is 37.78. The thresholds are as follows: Strongly Undervalued below 18.73, Undervalued between 18.73 and 28.26, Fairly Valued between 47.30 and 28.26, Overvalued between 47.30 and 56.82, and Strongly Overvalued above 56.82. The current Forward P/OCF of 24.79 falls within the Undervalued range.
27.14
P/FCF
Bio-Techne Corp. (TECH) has a current P/FCF of 27.14. The 5-year average P/FCF is 43.42. The thresholds are as follows: Strongly Undervalued below 21.67, Undervalued between 21.67 and 32.55, Fairly Valued between 54.29 and 32.55, Overvalued between 54.29 and 65.16, and Strongly Overvalued above 65.16. The current Forward P/FCF of 27.14 falls within the Undervalued range.
Bio-Techne Corp (TECH) has a current Price-to-Book (P/B) ratio of 4.33. Compared to its 3-year average P/B ratio of 5.81 , the current P/B ratio is approximately -25.46% higher. Relative to its 5-year average P/B ratio of 7.37, the current P/B ratio is about -41.29% higher. Bio-Techne Corp (TECH) has a Forward Free Cash Flow (FCF) yield of approximately 3.05%. Compared to its 3-year average FCF yield of 2.17%, the current FCF yield is approximately 40.68% lower. Relative to its 5-year average FCF yield of 1.97% , the current FCF yield is about 55.24% lower.
4.33
P/B
Median3y
5.81
Median5y
7.37
3.05
FCF Yield
Median3y
2.17
Median5y
1.97
Competitors Valuation Multiple
The average P/S ratio for TECH's competitors is 128.24, providing a benchmark for relative valuation. Bio-Techne Corp Corp (TECH) exhibits a P/S ratio of 6.76, which is -94.73% above the industry average. Given its robust revenue growth of 3.55%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of TECH decreased by 27.48% over the past 1 year. The primary factor behind the change was an increase in P/E Change from 55.21 to 116.52.
The secondary factor is the Revenue Growth, contributed 3.55%to the performance.
Overall, the performance of TECH in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch

HST
Host Hotels & Resorts Inc
15.860
USD
+0.89%

NCLH
Norwegian Cruise Line Holdings Ltd
24.730
USD
+1.77%

OVV
Ovintiv Inc
38.850
USD
-1.40%

RKLB
Rocket Lab Corp
46.095
USD
+4.12%

TXRH
Texas Roadhouse Inc
173.460
USD
+0.36%

NVT
nVent Electric PLC
88.970
USD
+1.09%

CIEN
Ciena Corp
90.520
USD
-0.39%

RTO
Rentokil Initial PLC
24.210
USD
-1.30%

CPT
Camden Property Trust
106.475
USD
-0.32%

AAL
American Airlines Group Inc
13.300
USD
+0.99%
FAQ

Is Bio-Techne Corp (TECH) currently overvalued or undervalued?
Bio-Techne Corp (TECH) is now in the Undervalued zone, suggesting that its current forward PE ratio of 26.66 is considered Undervalued compared with the five-year average of 43.05. The fair price of Bio-Techne Corp (TECH) is between 68.13 to 101.49 according to relative valuation methord. Compared to the current price of 53.86 USD , Bio-Techne Corp is Undervalued By 20.95% .

What is Bio-Techne Corp (TECH) fair value?

How does TECH's valuation metrics compare to the industry average?

What is the current P/B ratio for Bio-Techne Corp (TECH) as of Aug 18 2025?

What is the current FCF Yield for Bio-Techne Corp (TECH) as of Aug 18 2025?

What is the current Forward P/E ratio for Bio-Techne Corp (TECH) as of Aug 18 2025?
